APHB Financials 07/16/2014 05:35:27 Ampliphi Bios
Post# of 11
Posted On: 07/16/2014 6:35:24 AM
APHB Financials 07/16/2014 05:35:27
Ampliphi Biosciences Corp.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue 325 664
Cost of Revenue - -
Gross Profit 325 664
Operating Expenses
Research and Development 6,502 1,480
Sales, General and Admin. 6,259 3,177
Non-Recurring Items - -
Other - -
Operating Income (12,436) (3,993)
Income From Continuing Operations
Add'l Income/Expense Items (43,192) 103
Earnings Before Interest and Tax (55,628) (3,890)
Interest Expense 233 339
Earnings Before Tax (55,861) (4,229)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (55,861) (4,229)
Non Recurring Events
Discontinued Operations - 3,150
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (55,861) (1,079)
Preferred Stock and Other Adjustments (8,464) -
Net Income Applicable to Common Shareholders (64,325) (1,079)
Ampliphi Biosciences Corp.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue 325 664
Cost of Revenue - -
Gross Profit 325 664
Operating Expenses
Research and Development 6,502 1,480
Sales, General and Admin. 6,259 3,177
Non-Recurring Items - -
Other - -
Operating Income (12,436) (3,993)
Income From Continuing Operations
Add'l Income/Expense Items (43,192) 103
Earnings Before Interest and Tax (55,628) (3,890)
Interest Expense 233 339
Earnings Before Tax (55,861) (4,229)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (55,861) (4,229)
Non Recurring Events
Discontinued Operations - 3,150
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (55,861) (1,079)
Preferred Stock and Other Adjustments (8,464) -
Net Income Applicable to Common Shareholders (64,325) (1,079)
(0)
(0)Armata Pharmaceuticals, Inc. (ARMP) Stock Research Links
Scroll down for more posts ▼